Drug intelligence / Profile preview

17-methyl-17-alpha-dihydroequilenin

Development stage: Unknown
Modality: Small Molecules

Overview

**Description:** 17-methyl-17-alpha-dihydroequilenin is a synthetic steroidal estrogen and an experimental small molecule compound belonging to the class of estrogens and derivatives. It is structurally related to equilin and equilenin. The compound acts as an inhibitor of the estrogen receptor. There are no approved indications or marketed products containing this drug; it has not advanced beyond preclinical or early research phases[1][9][10]. Its mechanism involves binding to the estrogen receptor and modulating its activity[1]. No clinical trials or therapeutic uses have been reported.

Other names: (13alpha,17beta)-17-methylestra-1(10),2,4,6,8-pentaene-3,17-diolEstra-1,3,5(10),6,8-pentaene-3,17-diol, 17-methyl-, (17α)-

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on 17-methyl-17-alpha-dihydroequilenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 17-methyl-17-alpha-dihydroequilenin.

Explore the full profile